Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.44 |
| ▸ | MEN1 | O00255 | 6/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3063679 | 0.90 | ACHE (0.42) | ALDH1A1SMN1; SMN2ALOX15HSD17B10KMT2A | |
| SCHEMBL3055757 | 0.89 | ALDH1A1 (0.37) | ALDH1A1SMN1; SMN2ALOX15HSD17B10KMT2A | |
| SCHEMBL3056790 | 0.86 | PKM (0.36) | ALDH1A1SMN1; SMN2ALOX15HSD17B10KMT2A | |
| SCHEMBL3059848 | 0.86 | GAA (0.38) | ALDH1A1SMN1; SMN2ALOX15HSD17B10KMT2A | |
| SCHEMBL3054042 | 0.85 | NR3C1 (0.37) | ALDH1A1SMN1; SMN2ALOX15HSD17B10KMT2A | |
| SCHEMBL3045584 | 0.85 | ALDH1A1 (0.35) | ALDH1A1SMN1; SMN2ALOX15HSD17B10KMT2A | |
| SCHEMBL3049552 | 0.84 | THRB (0.38) | ALDH1A1SMN1; SMN2ALOX15HSD17B10KMT2A | |
| SCHEMBL3069190 | 0.84 | KMT2A (0.46) | ALDH1A1KMT2AMEN1MAPTUSP2 | |
| SCHEMBL3045610 | 0.83 | KMT2A (0.37) | ALDH1A1KMT2AMEN1MAPTKDM4E | |
| SCHEMBL3051665 | 0.83 | ALDH1A1 (0.39) | ALDH1A1SMN1; SMN2ALOX15HSD17B10KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541406-B2 | Thiadiazole derivatives for the treatment of neurodegenerative diseases | NV REMYND (BE) | 2013-09-24 | — | — | US | disclosed |
| US-20100261707-A9 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2010-10-14 | — | — | US | disclosed |
| US-20090233911-A2 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2009-09-17 | — | — | US | disclosed |
| US-20090054410-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233911-A2 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | ALDH1A1 1930/4885SMN1; SMN2 4/4885ALOX15 710/4885 |
| US-20100261707-A9 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | ALDH1A1 1930/4885SMN1; SMN2 4/4885ALOX15 710/4885 |
| US-20090054410-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | ALDH1A1 1930/4885SMN1; SMN2 4/4885ALOX15 710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.